TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  American Journal of Cancer Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 22206045PMCID PMC3236571
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chondrosarcoma of bone.

  2014cited by this paper
• Advances in Biology and Therapy of Multiple Myeloma

  2013cited by this paper
• Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles.

  2011cited by this paper
• Trail down‐regulates the release of osteoprotegerin (OPG) by primary stromal cells

  2011cited by this paper
• Bisphosphonate enhances TRAIL sensitivity to human osteosarcoma cells via death receptor 5 upregulation

  2011cited by this paper
• THE PRESENCE OF TRAIL–OPG COMPLEX IN HUMAN OSTEOSARCOMA AND HUMAN SALIVARY GLAND ADENOCARCINOMA

  2011influential reference
• A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

  2010cited by this paper
• Preclinical Evidence that Use of TRAIL in Ewing's Sarcoma and Osteosarcoma Therapy Inhibits Tumor Growth, Prevents Osteolysis, and Increases Animal Survival

  2010influential reference
• Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

  2010cited by this paper
• Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors.

  2010cited by this paper
• New insights into apoptosis signaling by Apo2L/TRAIL

  2010cited by this paper
• Soluble TRAIL could enhance bone destruction acting on Rank-ligand in estrogen-independent human breast cancer cell line MDA-MB-231.

  2010cited by this paper
• Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment.

  2010cited by this paper
• Doxorubicin coupled to penetratin promotes apoptosis in CHO cells by a mechanism involving c-Jun NH2-terminal kinase.

  2010cited by this paper
• Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL

  2010cited by this paper
• Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.

  2010cited by this paper
• Platelet‐derived growth factor receptor β inhibition increases tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) sensitivity

  2010cited by this paper
• Fenretinide-dependent upregulation of death receptors through ASK1 and p38α enhances death receptor ligand-induced cell death in Ewing's sarcoma family of tumours

  2010cited by this paper
• Osteosarcoma incidence and survival rates from 1973 to 2004

  2009cited by this paper
• International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons

  2009cited by this paper
• Primary osteogenic sarcoma with pulmonary metastasis: clinical results and prognostic factors in 91 patients.

  2009cited by this paper
• Genes that mediate breast cancer metastasis to the brain

  2009cited by this paper
• TRAIL as a target in anti-cancer therapy.

  2009cited by this paper
• Palmitoylation of the TRAIL receptor DR4 confers an efficient TRAIL-induced cell death signalling.

  2009cited by this paper
• Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.

  2009cited by this paper
• Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

  2009cited by this paper
• TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis.

  2008cited by this paper
• Positive and negative signaling components involved in TNFα-induced NF-κB activation

  2008cited by this paper
• A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies

  2008cited by this paper
• TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8.

  2008cited by this paper
• Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.

  2008cited by this paper
• TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development.

  2008cited by this paper
• Positive and negative signaling components involved in TNFalpha-induced NF-kappaB activation.

  2008cited by this paper
• Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF‐1 receptor by the pediatric preclinical testing program

  2008cited by this paper
• Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5

  2008cited by this paper
• Breast adenocarcinoma MCF-7 cell line induces spontaneous osteoclastogenesis via a RANK-ligand-dependent pathway.

  2008cited by this paper
• Proteasome inhibitor Bortezomib induces cell-cycle arrest and apoptosis in cell lines derived from Ewing’s sarcoma family of tumors and synergizes with TRAIL

  2008cited by this paper
• An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.

  2007influential reference
• Interferon- (cid:1) Sensitizes Resistant Ewing’s Sarcoma Cells to Tumor Necrosis Factor Apoptosis-Inducing Ligand-Induced Apoptosis by Up-Regulation of Caspase-8 Without Altering Chemosensitivity

  2007cited by this paper
• TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.

  2007cited by this paper
• Bone marrow stromal cells promote growth and survival of prostate cancer cells.

  2007cited by this paper
• Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing’s sarcoma cells

  2007cited by this paper
• DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells

  2007cited by this paper
• Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption.

  2007cited by this paper
• Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers

  2007cited by this paper
• Receptor-mediated Endocytosis Is Not Required for Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis*

  2007cited by this paper
• LKB1 is crucial for TRAIL-mediated apoptosis induction in osteosarcoma.

  2007cited by this paper
• Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling.

  2007cited by this paper
• INVESTIGATING THE INTERACTION BETWEEN OSTEOPROTEGERIN AND RANKL OR TRAIL: EVIDENCE FOR A PIVOTAL ROLE FOR OSTEOPROTEGERIN IN REGULATING TWO DISTINCT PATHWAYS

  2007influential reference
• Cell death modalities: classification and pathophysiological implications

  2007cited by this paper
• Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis

  2007cited by this paper
• Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL

  2007cited by this paper
• Barriers to effective TRAIL-targeted therapy of malignancy.

  2007cited by this paper
• Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death.

  2007cited by this paper
• Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

  2007cited by this paper
• Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways.

  2007cited by this paper
• TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma

  2006cited by this paper
• Differential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2

  2006cited by this paper
• Transduction of tumor necrosis factor-related apoptosis-inducing ligand into hematopoietic cells leads to inhibition of syngeneic tumor growth in vivo.

  2006cited by this paper
• TRAIL-R4-beta: a new splice variant of TRAIL-receptor 4 lacking the cysteine rich domain 1.

  2006cited by this paper
• Preclinical Differentiation between Apparently Safe and Potentially Hepatotoxic Applications of TRAIL Either Alone or in Combination with Chemotherapeutic Drugs

  2006cited by this paper
• Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells.

  2006cited by this paper
• Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells.

  2006cited by this paper
• Death-receptor activation halts clathrin-dependent endocytosis

  2006cited by this paper
• Osteoprotegerin (OPG) Expression by Breast Cancer Cells in vitro and Breast Tumours in vivo – A Role in Tumour Cell Survival?

  2005cited by this paper
• Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts

  2005cited by this paper
• Contribution of Epigenetic Silencing of Tumor Necrosis Factor–Related Apoptosis Inducing Ligand Receptor 1 (DR4) to TRAIL Resistance and Ovarian Cancer

  2005cited by this paper
• Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis

  2005cited by this paper
• Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis.

  2005influential reference
• Childhood cancer survival trends in Europe: a EUROCARE Working Group study.

  2005cited by this paper
• TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL.

  2005cited by this paper
• The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.

  2004cited by this paper
• Sensitivity of fresh isolates of soft tissue sarcoma, osteosarcoma and giant cell tumour cells to Apo2L/TRAIL and doxorubicin.

  2004cited by this paper
• Cell death: critical control points.

  2004cited by this paper
• TRAIL Inhibits Tumor Growth but Is Nontoxic to Human Hepatocytes in Chimeric Mice

  2004cited by this paper
• Pharmacological management of Ewing sarcoma family of tumours

  2004cited by this paper
• Deficient Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Death Receptor Transport to the Cell Surface in Human Colon Cancer Cells Selected for Resistance to TRAIL-induced Apoptosis*

  2004cited by this paper
• TRAIL-R as a negative regulator of innate immune cell responses.

  2004influential reference
• Interferon γ Enhances the Effectiveness of Tumor Necrosis Factor-Related Apoptosis–Inducing Ligand Receptor Agonists in a Xenograft Model of Ewing’s Sarcoma

  2004cited by this paper
• Following a TRAIL: Update on a ligand and its five receptors

  2004cited by this paper
• Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus

  2004cited by this paper
• Reduced Apoptosis and Ameliorated Listeriosis in TRAIL-Null Mice1

  2004cited by this paper
• Review Cell Death: Critical Control Points Another Line of Evidence for the Importance of Caspases in Cell Death Came From

  2004cited by this paper
• Osteoprotegerin (OPG) Produced by Bone Marrow Stromal Cells Protects Breast Cancer Cells from TRAIL-Induced Apoptosis

  2004cited by this paper
• Interferon gamma enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma.

  2004cited by this paper
• Sensitization of multidrug resistant human ostesarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase.

  2004cited by this paper
• Human Bone Marrow Stromal Cells Protect Prostate Cancer Cells From TRAIL‐Induced Apoptosis

  2004cited by this paper
• Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.

  2003cited by this paper
• Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL−/− mice

  2003cited by this paper
• Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor‐related apoptosis‐inducing ligand‐induced caspase‐8 activation, apoptosis and loss of mitochondrial membrane potential

  2003cited by this paper
• TRAIL Promotes the Survival and Proliferation of Primary Human Vascular Endothelial Cells by Activating the Akt and ERK Pathways

  2003cited by this paper
• Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy.

  2003cited by this paper
• TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis.

  2003cited by this paper
• Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy

  2003cited by this paper
• TRAIL-induced signalling and apoptosis.

  2003cited by this paper
• Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.

  2002influential reference
• Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development

  2002cited by this paper
• Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice1

  2002cited by this paper
• Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to apo2l/trail‐induced apoptosis

  2002cited by this paper
• Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells

  2001cited by this paper

• Antitumor effects of natural killer cells derived from gene-engineered human-induced pluripotent stem cells on hepatocellular carcinoma

  2025cites this paper
• In vitro and in vivo discrepancy in inducing apoptosis by mesenchymal stromal cells delivering membrane-bound tumor necrosis factor-related apoptosis inducing ligand in osteosarcoma pre-clinical models.

  2018cites this paper
• N-Acetyl-Glucosamine Sensitizes Non-Small Cell Lung Cancer Cells to TRAIL-Induced Apoptosis by Activating Death Receptor 5

  2018cites this paper
• Efficacy of ONC201 in Desmoplastic Small Round Cell Tumor1

  2018cites this paper
• Fn 14 $ TRAIL fusion protein is oligomerized by TWEAK into a superef fi cient TRAIL analog

  2017cites this paper
• TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: Pre-clinical and clinical data.

  2017influential citation
• TRAIL causes deletions at the HPRT and TK1 loci of clonogenically competent cells.

  2016cites this paper
• TRAIL delivered by mesenchymal stromal/stem cells counteracts tumor development in orthotopic Ewing sarcoma models

  2016cites this paper
• TRAIL-based therapy in pediatric bone tumors: how to overcome resistance.

  2015cites this paper
• Mesenchymal Progenitors Expressing TRAIL Induce Apoptosis in Sarcomas

  2015cites this paper
• Conference report on the 28th annual meeting of the European Musculo-Skeletal Oncology Society, 29 April–1 May 2015, Athens

  2015cites this paper
• Death ligand concentration and the membrane proximal signaling module regulate the type 1/type 2 choice in apoptotic death signaling

  2015influential citation
• Kinetic Monte Carlo study of the type1/type 2 choice in apoptosis elucidates selective killing of cancer cells under death ligand induction

  2015cites this paper
• Bone microenvironment signals in osteosarcoma development

  2015cites this paper
• Bone Metastasis: Molecular Mechanisms Implicated in Tumour Cell Dormancy in Breast and Prostate Cancer.

  2015cites this paper
• Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells

  2015cites this paper
• STAT-6 mediates TRAIL induced RANK ligand expression in stromal/preosteoblast cells.

  2015cites this paper
• Tanshinone IIA Facilitates TRAIL Sensitization by Up-regulating DR5 through the ROS-JNK-CHOP Signaling Axis in Human Ovarian Carcinoma Cell Lines.

  2015cites this paper
• Osteoprotegerin: multiple partners for multiple functions.

  2013cites this paper
• Elucidates the Type 1 / Type 2 Choice in Apoptotic Death Signaling in Healthy and Cancer Cells

  2013cites this paper
• Synergistic Effect of Subtoxic-dose Cisplatin and TRAIL to Mediate Apoptosis by Down-regulating Decoy Receptor 2 and Up-regulating Caspase-8, Caspase-9 and Bax Expression on NCI-H460 and A549 Cells

  2013cites this paper
• Monte Carlo study elucidates the type 1/type 2 choice in apoptotic death signaling in normal and cancer cells

  2013cites this paper
• Targeted therapies for bone sarcomas.

  2013cites this paper
• Oncoapoptotic signaling and deregulated target genes in cancers: special reference to oral cancer.

  2013cites this paper
• Präklinische Evaluation von Titanocenverbindungen als potentielle Zytostatika

  2013cites this paper
• Decreased Affinity of Recombinant Human Tumor Necrosis Factor-related Apoptosis-inducing Ligand (rhTRAIL) D269H/E195R to Osteoprotegerin (OPG) Overcomes TRAIL Resistance Mediated by the Bone Microenvironment

  2013cites this paper
• Bone Microenvironment Overcomes TRAIL Resistance Mediated by D 269 H / E 195 R to Osteoprotegerin ( OPG ) Apoptosis-inducing Ligand ( rhTRAIL ) Tumor Necrosis Factor-related Decreased Affinity of Recombinant Human Cell

  2013cites this paper
• Monte Carlo Study Elucidates the Type 1/Type 2 Choice in Apoptotic Death Signaling in Healthy and Cancer Cells

  2013cites this paper
• New insights into the role of sequestosome 1/p62 mutant proteins in the pathogenesis of Paget's disease of bone.

  2013cites this paper
• Sarcomas as a mise en abyme of mesenchymal stem cells: exploiting interrelationships for cell mediated anticancer therapy.

  2012cites this paper
• Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors.

  2012cites this paper